Arsenite trioxide (As 2 O 3 ) induces apoptosis in several cell lines by disturbing key signal transduction pathways through its oxidative properties. Here, we report that As 2 O 3 also induces the phosphorylation of the retinoid receptor RXRa, subsequent to oxidative damages and the activation of the stress-activated protein kinases cascade (JNKs). We also report that RA amplifies both As 2 O 3 -induced phosphorylation of RXRa and apoptosis. Taking advantage of 'rescue' F9 cell lines expressing RXRa mutated at its phosphorylation sites, in an RXRa null background, we provide evidence that RXRa is a key element involved in that potentiating effect. Finally, we demonstrate that As 2 O 3 also abrogates the transactivation of RA-target genes.
Introduction
Arsenite trioxide (As 2 O 3 ) has long been known to be toxic and to act as a carcinogen involved in the human skin, lung, kidney and urinary bladder cancers (Huang et al., 2004; Shi et al., 2004) . Although the mechanisms underlying most of the effects of As 2 O 3 are still not well understood, it is well established that As 2 O 3 is an oxidative stress agent (Kitchin and Ahmad, 2003) , which, through the production of reactive oxygen species and the modification of thiol groups, induces protein and DNA damages (Meriin et al., 1999; Kapahi et al., 2000; Huang et al., 2004; Shi et al., 2004) . These oxidative effects of As 2 O 3 result in the disruption of key signal transduction pathways, leading to the induction of apoptosis (Li et al., 2002) . Indeed, As 2 O 3 activates the MAPK signaling pathways (Cavigelli et al., 1996; Meriin et al., 1999; Verma et al., 2002) and therefore induces the phosphorylation of a subset of transcription factors (AP-1, Elk, ATF2, CREB and others) (Bebien et al., 2003) , PML (Hayakawa and Privalsky, 2004) and histones (Li et al., 2002 (Li et al., , 2003a He et al., 2003) . This leads to the increased transcription of critical apoptosisand proliferation-associated genes including among others, the proto-oncogenes c-fos, c-jun and Egr-1 (Lim et al., 1998; Bernstam and Nriagu, 2000; Liu et al., 2003) and caspases (Li et al., 2002) .
In vitro, As 2 O 3 also shows proapoptotic activities in a number of cancer cells including the acute promyelocytic leukemia (APL) cells (de The et al., 1990; Roussel and Lanotte, 2001 ). Most interestingly, RA was found to synergize with the apoptotic properties of As 2 O 3 (Zhang et al., 2001; Zhu et al., 2002b; Shen et al., 2004) . Thus, RA and As 2 O 3 represent two examples of drugs that can interfere with each other. However, the mechanisms underlying such a convergence are still not well understood.
RA, the most potent biologically active metabolite of vitamin A, exerts its action through two families of nuclear receptors, the RARs (a, b, g) and the RXRs (a, b, g), which bind as RAR/RXR heterodimers to response elements located in the promoters of RAtarget genes (Chambon, 1996; Laudet and Gronemeyer, 2001) . As a consequence, RA induces cell differentiation and growth arrest (Altucci and Gronemeyer, 2001a, b) . Recent studies revealed that retinoid receptors integrate not only the retinoid signal but also multiple signaling pathways through their phosphorylation (RochetteEgly, 2003; Bastien and Rochette-Egly, 2004 ) (see Figure 1a) . Indeed, the N-terminal domains of RARs and RXRs have been shown to be targets for prolinedirected kinases. RARs are phosphorylated at one residue (Ser 77 in RARa1 and Ser 68 in RARg2) Bastien et al., 2000) by cdk7/ cyclin H associated to the general transcription factor TFIIH. In response to RA, RARg2 is also phosphorylated by p38MAPK at the nearby serine residue (S66) (Gianni et al., 2002a) . These phosphorylation processes are crucial for RAR activity. In contrast, RXRa can be phosphorylated at three residues (S61, S75 and T87, Figure 1a ) by MAPKs in response to RA (Gianni et al., 2003) or to genotoxic stresses such as UV radiations (Adam-Stitah et al., 1999; Lee et al., 2000) .
RARs and RXRs being targets for protein kinases, we aimed at determining whether As 2 O 3 and RA could interfere with each other through the phosphorylation of these receptors. In the present report, we demonstrate that As 2 O 3 induces the phosphorylation of RXRa in several cell lines, either APL or not APL, through the activation of JNKs. As 2 O 3 also induces apoptosis and this effect is amplified by RA. We therefore investigated whether phosphorylated RXRa was involved in this cooperation between As 2 O 3 and RA for apoptosis. Taking advantage of 'rescue' F9 cell lines reexpressing RXRa mutated at its phosphorylation sites, in an RXRa null background, we provide evidence that RXRa is a key element involved in the cooperation between RA and As 2 O 3 for apoptosis, due to its ability to integrate the retinoid signal and to be phosphorylated by JNKs.
Results

Arsenic trioxide (As 2 O 3 ) induces RXRa phosphorylation
In a previous report (Adam-Stitah et al., 1999) , we demonstrated that a marked upward shift in the electrophoretic mobility of RXRa is characteristic of the phosphorylation of the N-terminal region at three residues (S61, S75 and T87) (Figure 1a) , in response to genotoxic stresses such as UV radiations. Therefore, we investigated whether RXRa could also be targeted for phosphorylation in response to oxidative stress agents such as As 2 O 3 . Treatment of COS-1 cells overexpressing RXRa, with As 2 O 3 resulted in an upward shift in the electrophoretic mobility of RXRa (Figure 1b , compare lanes 1 and 2). This As 2 O 3 -induced shift in the electrophoretic mobility of RXRa reflects the phosphorylation of the three residues located in the N-terminal region, as it was no longer observed in COS-1 cells transfected with an expression vector encoding RXRa mutated at these phosphorylation sites (Figure 1b , lanes 3 and 4).
As 2 O 3 also induced an upward shift of RXRa in the mouse F9 embryocarcinoma cell line (Figure 1a , lanes 5 and 6), which represents an autonomous cell system model responsive to RA (Rochette-Egly and Chambon, 2001 ). This upshift was transient, starting at 30 min and disappearing at 5 h ( Figure 1c , lanes 1-6). It was detected with As 2 O 3 concentrations ranging from 1 to 25 mM (Figure 1c , lanes 7-12). It was no longer observed in an F9 rescue line re-expressing RXRa mutated at its phosphorylation sites in an RXRa null background, (Figure 1b , lanes 7 and 8), confirming that As 2 O 3 induces the phosphorylation of the N-terminal domain of RXRa. Such a mutant F9 rescue line represents an interesting tool to study the role of RXRa phosphorylation caused by As 2 O 3 , and thus was used in most of the experiences described below.
Of note is that the shift in the electrophoretic mobility of RXRa could be also seen in a number of other cells such as Head and Neck Squamous Cancer Cells (SqCYY1 cell line) (Figure 1b , lanes 9-13) or acute promyelocytic leukemic (APL) cells (NB4 cell line) (data not shown and see below Figure 8b ). Altogether, these results indicate that As 2 O 3 induces the phosphorylation of the N-terminal AF-1 domain of RXRa.
The As 2 O 3 -induced RXRa phosphorylation involves JNKs
There is growing evidence that As 2 O 3 exerts its effects through disturbing many signaling pathways including the activation of multiple MAPK cascades (Bebien et al., 2003) . Therefore, we investigated which kinase(s) accounted for As 2 O 3 -induced RXRa phosphorylation in F9 cells. As 2 O 3 induced the activation of Erks, p38 MAPK and JNKs, as evidenced by an increase in the amount of the active phosphorylated forms of these As 2 O 3 is a stress agent that induces oxidative damage to several cellular proteins subsequently to the generation of hydrogen peroxide (H 2 O 2 ) and highly reactive hydroxyl radicals ( OH) (Iordanov and Magun, 1999; Kitchin and Ahmad, 2003) . To test whether this accounted for MAPK activation by As 2 O 3 , we pretreated F9 cells with N-acetyl-cysteine (NAC), which exerts an antioxidant role via its capability to scavenge H 2 O 2 and OH. NAC completely blocked the activation of all MAPKs (Figure 2c ). It also abolished the ability of As 2 O 3 to induce RXRa phosphorylation (Figure 2c , upper panel), indicating that the effects of As 2 O 3 on RXRa phosphorylation reflect the oxidative properties of this stress agent.
Interestingly, in F9 cells, As 2 O 3 also increased the amount of active Akt (P-Akt), as assessed by immunoblotting with antibodies specific for the phosphorylated form at serine 473 ( Figure 2c , lower panels, lane 2 and Figure 3a , lane 3). This increase was abrogated by the antioxidant NAC (Figure 2c , lanes 3-5) and by the PI3K inhibitors LY294002 (Figure 3a , lane 4) or wortmannin (data not shown). Of note is that LY294002 also abrogated the increase in the amount of active P-JNKs and subsequently the phosphorylation of RXRa (Figure 3a ). These data suggest that the activation of JNKs and the subsequent phosphorylation of RXRa by As 2 O 3 would result from the activation of the PI3K/Akt pathway. Accordingly, overexpression of an active (a) form of Akt along with RXRa in COS-1 cells enhanced both the activation of JNKs (data not shown) and the phosphorylation of RXRa (Figure 3b , lanes 3-5) induced by As 2 O 3 . In contrast, overexpression of a dominant-negative (dn) form of Akt markedly decreased RXRa phosphorylation (Figure 3b , lanes 8-10), corroborating that the hyperphosphorylation of RXRa by JNKs results from the activation of Akt.
The As 2 O 3 -induced activation of JNKs has been shown to result not only from the activation of upstream kinases but also from the phosphorylation and subsequent inhibition of a JNK-specific phosphatase (M3/6 phosphatase) (Theodosiou and Ashworth, 2002) . Therefore, we evaluated the consequences of overexpressing this phosphatase on the As 2 O 3 -induced phosphorylation of RXRa. Coexpression of the M3/6 phosphatase with RXRa in COS-1 cells inhibited the As 2 O 3 -induced upwardshift of RXRa ( Figure 3c , compare lanes 3-5 to lane 2). However, the shift was restored subsequently to the coexpression of the active form of Akt ( Figure 3c , lane 6). Thus, one can postulate that the As 2 O 3 -induced phosphorylation of RXRa by JNKs results from the inhibition of the M3/6 phosphatase subsequent to the activation of Akt.
As 2 O 3 induces the degradation of the RAR heterodimerization partner
We further investigated whether As 2 O 3 would also affect the phosphorylation of the RAR (RARa or RARg) heterodimeric partner of RXRa. In fact, no variation in the phosphorylation of RARg or RARa overexpressed in COS-1 cells could be detected in response to As 2 O 3 (data not shown), as assessed by immunoblotting with antibodies recognizing specifically the phosphorylated form ( Figure 1a ) (Gianni et al., 2002b; Keriel et al., 2002) . However, As 2 O 3 induced a rapid decrease in the amount of RARg and RARa ( Figure 4a ) as soon as 1 h following its addition. RARg and RARa mutated at their phosphorylation sites located in the N-terminal AF-1 domain (RARgS66/68A and RARaS77A) were decreased as efficiently as the WT receptors in transfected COS cells (Figure 4a ), in agreement with the fact that As 2 O 3 does not affect RARs phosphorylation.
In F9 cells, in which RARg is the main RAR isotype (Rochette-Egly and Chambon, 2001), As 2 O 3 also decreased RARg levels (Figure 4b ), in a concentrationdependent manner. Indeed, RARg levels decreased very rapidly (within 1-2 h) with As 2 O 3 concentrations ranging between 1 and 25 mM ( Figure 4b ) and later with lower As 2 O 3 concentrations (5 mM). As 2 O 3 (1 mM) did not affect RARg levels at all (Figure 4b ). Interestingly, similar decreases were observed in F9 cells expressing RARg mutated at its phosphorylation sites (RARgS66/ 68A) in an RARg null background (Figure 4b ), confirming that this process is phosphorylation-independent. The As 2 O 3 -induced decrease is the amount of RARg that resulted from the degradation of the protein rather than from a decrease in the transcription of RARg, since the amount of RNA was not affected as assessed by realtime RT-PCR (data not shown). Accordingly, it was partially reversed upon treatment of the cells with the proteasome inhibitor MG132 (Figure 4c, lanes 1-4) . It was also reversed by NAC (Figure 4c, lanes 5-8) , indicating that the oxidative properties of As 2 O 3 account for RARg degradation.
Finally, As 2 O 3 also induced the disappearance of RARa in several cell lines (data not shown) such as the SqCC/Y1 and NB4 cell lines (Gianni et al., 1998; Zhu et al., 2001; Shen et al., 2004) .
As 2 O 3 induces apoptosis independently of RXRa
In F9 cells, As 2 O 3 triggered apoptosis within 6 h as assessed by the cleavage and activation of caspase 7 (Figure 5a ) and caspase 9 ( Figure 5b ). As 2 O 3 also increased significantly DEVD-amc hydrolytic activity (Figure 5c ), which reflects the activity of caspase-3 like proteases including predominantly caspase 3 and Mologni et al., 1999) . This apoptotic activity occurred at As 2 O 3 concentrations as low as 0.1-1 mM ( Figure 5c ). As 2 O 3 -induced apoptosis was accompanied by the appearance of a characteristic apoptotic DNA ladder of fragmented DNA (Figure 5d ).
In F9 cells, As 2 O 3 also induced markedly, as assessed by quantitative real-time RT-PCR, the expression of Egr-1, which is the paradigm of the As 2 O 3 -target genes associated to apoptosis (Lim et al., 1998; Bernstam and Nriagu, 2000) . This As 2 O 3 -induced induction of Egr-1 expression occurred as soon as 2 h (Figure 5e ) and involved JNKs as it was abrogated by the JNK inhibitor SP600125 (Figure 5f, compare lanes 3 and 4) but not by the MEK1 and p38MAPK inhibitors (data not shown). These results are consistent with other reports indicating that JNKs mediate As 2 O 3 signaling to several target genes through the phosphorylation of multiple transcription regulators (Bebien et al., 2003; Li et al., 2003b; Xi and Kersh, 2003; Buchwalter et al., 2004) . Accordingly, a 1-h treatment of F9 cells with As 2 O 3 induced the phosphorylation and subsequent activation of c-Jun and c-Fos as assessed in a TransAM assay (data not shown).
Then we investigated whether phosphorylated RXRa might play any role in the As 2 O 3 -induced activation of Egr-1. With that aim, we took advantage of our F9 cell lines either ablated for RXRa (Clifford et al., 1996) or re-expressing, in an RXRa null background, RXRa mutated at the phosphorylation sites. Our results clearly show that, in these cell lines, Egr-1 was as efficiently activated by As 2 O 3 as in the parental WT cell line (Figure 6a ). The Apoptotic DNA ladder of fragmented DNA was also similarly induced in these cell lines (Figure 6b ), indicating that RXRa is not involved in this process.
RA potentiates As 2 O 3 -induced apoptosis through phosphorylated RXRa
Since a number of studies reported synergistic effects of RA and As 2 O 3 on apoptosis of APL cells (Zhang et al., 2001; Zhu et al., 2002b; Shen et al., 2004) , we analysed whether it also occurred in non-APL cells such as F9 cells. Our results clearly show that RA markedly enhanced the apoptotic effect of As 2 O 3 on F9 cells. Indeed, RA alone was unable to induce apoptosis (Figure 7a and b, lane 5 and Figure 7d , lane 2) but increased the As 2 O 3 -induced DEVD-amc hydrolytic activity (Figure 7a ) and cleavage of caspase 7 (Figure 7b, lanes 6-8) . This potentiating effect of RA was rather clear at low As 2 O 3 concentrations (0.1-1 mM), suggesting that it renders the cells more sensitive to As 2 O 3 -induced apoptosis. RA also markedly enhanced (three-fold) the As 2 O 3 -induced activation of Egr-1 (Figure 7c, compare lanes 3 and 4) and the appearance of the apoptotic DNA ladder induced by As 2 O 3 (Figure 7d, compare lanes 3 and 4) . Then, because RA had been reported to interfere with several MAPK pathways (Caelles et al., 1997; Lee et al., 1999) , we attempted to investigate whether its potentiating effect on As 2 O 3 -induced apoptosis involved JNKs and/or phosphorylated RXRa. When combined with As 2 O 3 , RA increased the As 2 O 3 -induced activation of JNKs (Figure 8a , lane 4), but not the As 2 O 3 -induced activation of Akt (Figure 8a , lower panels), indicating that As 2 O 3 and RA activate JNKs through distinct mechanisms. RA also markedly enhanced the ability of As 2 O 3 to induce RXRa phosphorylation at low (1 mM) concentrations (Figure 8a and b, lanes 4 and 5) . This effect of RA was abolished by the JNK inhibitor (Figure 8b , lane 6). This synergy was evidenced at the same low concentrations of As 2 O 3 (0.1-1 mM) as for apoptosis (Gianni et al., 1998; Zhang et al., 2001; Zhu et al., 2002b) .
Altogether, these results strongly suggest that RA cooperates with As 2 O 3 for apoptosis increasing the phosphorylation of RXRa by JNKs, either in APL or in non-APL cells. Such a hypothesis was corroborated by the observation that the JNK inhibitor also abolished the potentiating effect of RA on the As 2 O 3 -induced activation of Egr-1 (Figure 7c, lane 5) . Then, to further understand whether phosphorylated RXRa might play a role in the amplification by RA of the apoptotic effect of As 2 O 3 , we again took advantage of our F9 cell lines either ablated for RXRa or re-expressing, in an RXRa null background, RXRa mutated at the phosphorylation sites. Our results clearly show that in F9 cells ablated for RXRa Figure 9b , lanes 7-9). Collectively, all these results converge towards the conclusion that RA potentiates the As 2 O 3 -induced apoptosis through phosphorylated RXRa.
As 2 O 3 abrogates the transactivation of RA-target genes
What is the physiological relevance of the As 2 O 3 -induced RXRa phosphorylation and RARg degradation to the activation of the RA-target genes? Following our recent study (Gianni et al., 2003) demonstrating that In F9 cells, a number of RA-target genes such as CYP26, RARb2 and Stra4 are activated after 6-8 h of RA treatment (Figure 10 ) (Rochette-Egly and Chambon, 2001 ). As 2 O 3 did not affect, significantly up to 8 h, the basal expression of CYP26, RARb2 and Stra4 (Figure 10a) . Surprisingly, we found that when added simultaneously to RA, As 2 O 3 (1-25 mM) abrogated the activation of these genes in a dose-dependent manner (Figure 10a ). Most importantly, in the rescue F9 cell line re-expressing, in an RXRa À/À background, RXRa mutated at the phosphorylation sites, the target genes were less efficiently induced by RA but were still inhibited by As 2 O 3 (Figure 10b ). In addition, a pretreatment of the cells with the JNK inhibitor SP600125 and the PI3K inhibitor LY294002, which have been shown to inhibit the As 2 O 3 -induced phosphorylation of RXRa (see Figure 2) , did not reverse the inhibition of the RA-target genes by As 2 O 3 (data not shown).
Collectively, these results indicate that the observed inhibition of the RA-target genes would not result from the As 2 O 3 -induced phosphorylation of RXRa. It could not be attributed to the degradation of RARg as the RA-target genes were inhibited in response to As 2 O 3 concentrations as low as 1 mM, which do not affect RARg levels (see Figure 5b) . In fact, one could speculate that As 2 O 3 , through its oxidative properties, would rather alter the DNA bases located in the response elements of the target genes and/or inactivate cofactors specifically involved in the transactivation of RA-target genes. 
Discussion
Although functional interference between As 2 O 3 and retinoids had been observed in a variety of settings (Zhu et al., 2002a, b) , little is known about the precise mechanisms underlying the intracellular interplay between their respective signaling pathways. In this report, we provide the first evidence that RA potentiates the apoptotic activity of As 2 O 3 through phosphorylated RXRa.
In the present study, we demonstrate that As 2 O 3 induces apoptosis in non-APL cell lines, such as mouse embryocarcinoma cells (F9 cell line), as evidenced by the activation of caspases and the expression of Egr-1, which is the prototype of the As 2 O 3 target genes involved in apoptosis, and at the same concentrations (1 mM) described for APL cells (Gianni et al., 1998; Zhang et al., 2001; Zhu et al., 2002b; Shen et al., 2004) . The interesting feature of the present study is our finding that either in APL or in non-APL cells, As 2 O 3 also induces the phosphorylation of the nuclear retinoid receptor RXRa. By using specific kinase inhibitors and kinase expression vectors, we demonstrated that, although the different MAPKs cascades (Erks, p38MAPK and JNKs) are activated simultaneously by As 2 O 3 , only JNKs mediate the phosphorylation of RXRa, subsequent to oxidative damages induced by As 2 O 3 and to the activation of the PI3K/Akt pathway. As As 2 O 3 -induced apoptosis has been reported to involve the phosphorylation of several transcription factors (Bebien et al., 2003; Hayakawa and Privalsky, 2004) , these results challenged the hypothesis that RXRa might also play a role in this process. To address this hypothesis, we took advantage of our F9 rescue cell line expressing in an RXRa À/À background, RXRa mutated at its phosphorylation sites. Such a strategy allowed us to demonstrate that RXRa is not involved in the induction of apoptosis or in the activation of Egr-1 expression by As 2 O 3 , raising the hypothesis that other factors phosphorylated by the MAPK cascade would rather mediate the apoptotic effect of As 2 O 3 (Hayakawa and Privalsky, 2004) .
The interesting feature of the present study is our observation that, in F9 cells, RA potentiates the As 2 O 3 -induced apoptosis. This effect was evidenced at the same low As 2 O 3 concentrations described for APL cells (Gianni et al., 1998) , suggesting that some common mechanism should be involved. Accordingly, we found that RA potentiates the ability of As 2 O 3 to activate JNKs and to phosphorylate RXRa, both in F9 and in NB4 cells. By using the above F9 rescue cell lines, we provided evidence that phosphorylated RXRa plays a crucial role in this potentiating effect of RA. Thus, one can conclude that RA would help mediate the apoptotic effect of As 2 O 3 by activating RXRa and increasing its phosphorylation. Also, phosphorylated RXRa is required for the potentiation of Egr-1 induction. As the promoter of Egr-1 does not contain any RA response element (Sakaue et al., 2001) ), leading to a more effective recruitment of the transcriptional machinery and therefore to increased transcription. In agreement with such a hypothesis, the N-terminal domain of RXRa has been shown to interact with transcription regulators such as Bcl3 (Na et al., 1998) . Whether phosphorylated RXRa also modulates the expression of other genes involved in the control of cell death would require further investigation. Nevertheless, it is interesting to note that a similar synergy has been recently reported between IL-6 and glucocorticoids for the activation of the a2-macroglobulin gene (Lerner et al., 2003) . Thus, RXRa appears to be a key element in the cross-talk between RA and As 2 O 3, for apoptosis due to its ability to integrate both the retinoid and As 2 O 3 signals, through the phosphorylation of its N-terminal domain.
Alternatively, As 2 O 3 did not affect the phosphorylation of the RAR (either RARa or RARg) heterodimeric partner, but induced its rapid degradation, as previously reported for the fusion protein PML-RARa (Zhu et al., 1999 . Whether this degradation process depends on SUMO as described for PML-RARa or on the disruption of the interaction between RARs and corepressors (Hong et al., 2001) , which are known to protect nuclear receptors from proteolysis (Boudjelal et al., 2002) , will require further investigations. Nevertheless, although the As 2 O 3 -induced degradation of RARs was not amplified by RA, one cannot exclude that this degradation process helps phosphorylated RXRa to increase the activation of the As 2 O 3 target genes by liberating the dimerization surface.
Reciprocally, As 2 O 3 has been reported to synergize with RA for the differentiation of APL cells (Rego et al., 2000; Zhu et al., 2002a; Shen et al., 2004) . However, As 2 O 3 did not synergize with RA for the differentiation of F9 cells because of the rapid onset of apoptosis. In fact, we discovered that, in these cells, As 2 O 3 rather impaired the RA-induced activation of RA-target genes. All our results converge towards the conclusion that this effect does not involve the As 2 O 3 -induced MAPK pathways, nor RXRa phosphorylation or RARg degradation. As As 2 O 3 is a stress agent that induces oxidative damage of proteins (Meriin et al., 1999; Kapahi et al., 2000) , it is possible that it alters the DNA binding capacity of RARg/RXRa heterodimers. However, EMSA experiments (our unpublished observations) revealed that, at the onset of JNKs activation and RXRa hyperphosphorylation, the capacity of RARg/RXRa heterodimers to bind a cognate response element was not altered. Another alternative would be that, through its oxidative properties, As 2 O 3 alters DNA bases within RAREs and/or inactivates coregulators specifically involved in the transactivation of RA-target genes (Ghosh and Mitchell, 1999; Kessel et al., 2002; Nesnow et al., 2002; Schwerdtle et al., 2003) . Further investigations will be required to characterize these damaging effects and to analyse whether they contribute to the As 2 O 3 -induced apoptosis.
In summary, we provide new insights on how RA renders cells (either APL or non-APL) more sensitive to As 2 O 3 -induced apoptosis. Specifically, this study highlights the importance of RXRa as an integrator of the cross-talk between RA and As 2 O 3 through its phosphorylation by JNKs. Experiments are presently under way to identify proteins interacting with the phosphorylated N-terminal domain of RXRa. Work is also in progress to determine further how stress agents and retinoids interfere with each other. Learning more about the precise mechanisms of these drugs might allow us to modulate their apoptotic and/or carcinogenic effects. Indeed, this will have impacts on the choice of therapeutical strategies.
Materials and methods
Plasmid constructs
The pSG5-based expression vectors for mouse (m) RARg2, mRARg2S66/68A, mRARa1, mRARaS77A, mRXRa and mRXRaS61A/S75A/T87A were previously described Adam-Stitah et al., 1999; Bastien et al., 2000) . RXRaWT in pD402A was as in Bastien et al. (2002) . mRXRa mutated at the phosphorylation sites, in PD402A, was constructed by subcloning the XhoI-BglII fragment containing the mutations from the pSG5-mRXRa construct, into the same sites of pD402A-RXRaWT. The vectors for active and dominant-negative Akt containing an Myc-tag were purchased from Upstate Biotechnology Inc. The vector for M3/6 phosphatase, N-terminally myc-tagged in pMT-SM was provided by A Theodosiou (Athens, Greece).
Chemicals
All-trans retinoic acid, LY294002, NAC, Wortmannin and AS 2 O 3 were from Sigma-Aldrich. SP600125, SB203580, and MG-132 were from Calbiochem. PD98059 was from Cell Signaling Technology, Inc.
Antibodies
Rabbit polyclonal antibodies against RARa [RPa(F)], RARg [RPg(F)] and RXRa [RPXa(A)] have been previously described (Gaub et al., 1992; Rochette-Egly et al., 1994; Bastien et al., 2000) . Rabbit polyclonal antibodies against JNKs, p38MAPK and Akt and their active phosphorylated forms, P-JNK (Thr183/Tyr185), P-p38MAPK (Thr180/Tyr182) and P-Akt (Ser473) were from Cell Signaling Technology, Inc. (USA). The antibodies against Erks, the phosphorylated forms of Erks (P-Erk1 and P-Erk2) and b-actin were from Santa Cruz Biotechnology, Inc. Anti-Myc tag antibodies were from Upstate Biotechnology Inc.
Cell lines, transfections and immunoblotting
F9 cells WT, RXRa
À/À and re-expressing RXRa in an RXRa null background were previously described (Clifford et al., 1996; Bastien et al., 2002) . The rescue line re-expressing RARg2S66/68A in a RARg null background was as described (Taneja et al., 1997) . The rescue cell line expressing RXRa mutated at the phosphorylation sites in an RXRa null background was established as described (Bastien et al., 2002) .
Head and neck squamous cancer cells (SqCC/Y1 cell line) were provided by Dr Lotan and grown as described in Oridate et al. (1996) . The NB4 APL cell line was provided by M Lanotte and grown under the same conditions as previously reported (Benoit et al., 1999) . COS-1 cells were transiently transfected in six-well plates using the DMRIE-C reagent, according to the manufacturer's protocol (GIBCO-BRL-Life Technologies). All transfections contained 2.5 mg DNA including the RAR-and RXRa-pSG5-based expression vectors (0.05 mg each), the b-galactosidase expression vector pCH110 (0.5 mg) to correct for variations in transfection efficiency and bluescript as a carrier. After a 16-h incubation with DNA, cells were washed and further incubated in medium with or without RA (10 À7 M) and As 2 O 3 . Cytosolic and nuclear extracts were prepared as previously described (Gianni et al., 2002a, b) and resolved by SDS-PAGE (10%), electrotransferred onto nitrocellulose membranes and immunoprobed. The protein-antibody complexes were detected by chemiluminescence according to the manufacturer's protocol (Amersham Biosciences).
RNA isolation and real-time RT-PCR
Total RNAs were isolated using the guanidinium thiocyanate method and aliquots (50 ng) were subjected to real-time quantitative RT-PCR by using the SYBR Green Light-Cycler Detection System (Roche, Idaho Technologies). Transcript levels were normalized according to 36B4 transcripts, which are unresponsive to retinoids and 
TransAMt
The TransAM AP-1 family kit (Active Motif) was used to detect and quantify the activation of the heterodimeric complexes derived from the Fos and Jun families. This kit provides antibodies recognizing the activated and phosphorylated forms of c-Fos, Fos B and c-Jun specifically bound to an oligonucleotide containing a consensus-binding site, immobilized on plates. F9 cell nuclear extracts (3 mg) were incubated with the oligonucleotide-coated wells. Then the bound phosphorylated AP-1 complexes were detected with a primary antibody recognizing the phosphorylated forms, followed by anti-IgG HRP conjugate. The interaction is quantified by spectrophotometry at 450 nm.
Analysis of apoptosis
As 2 O 3 -induced apoptosis was analysed by immunoblotting of the cytosolic extracts prepared from F9 cells with rabbit polyclonal antibodies recognizing both full-length and cleaved mouse caspase 9 (Cell Signaling Technology) and with mouse monoclonal antibodies recognizing procaspase 7 (Transduction Laboratories). DEVD-amc hydrolytic activity was determined as described (Mologni et al., 1999) . The DNA fragmentation assays were performed as described previously (Clifford et al., 1996) .
